TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 25375848

Group type: EXPERIMENTAL
Intervention: AcrySof ReSTOR SN6AD2 IOL (+2.5 D near add)
Number of subjects: 62

Group type: COMPARATOR
Intervention: AcrySof ReSTOR SN6AD1 IOL (+3.0 D near add)
Number of subjects: 62
Study: 22150410

Group type: EXPERIMENTAL
Intervention: Morphine 100 μg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Morphine 200 μg
Number of subjects: 144

Group type: EXPERIMENTAL
Intervention: Morphine 300 μg
Number of subjects: 144

Group type: COMPARATOR
Intervention: Placebo (saline)
Number of subjects: 144
Study: 20332178

Group type: EXPERIMENTAL
Intervention: Small group asthma education programme and locally adapted paediatric asthma guidelines
Number of subjects: 411

Group type: COMPARATOR
Intervention: Adapted paediatric asthma guidelines
Number of subjects: 411

Group type: COMPARATOR
Intervention: Unrelated educational intervention
Number of subjects: 411
Study: 18524783

Group type: EXPERIMENTAL
Intervention: Remifentanil-propofol
Number of subjects: 44

Group type: EXPERIMENTAL
Intervention: Remifentanil-sevoflurane
Number of subjects: 44
Study: 15801332

Group type: EXPERIMENTAL
Intervention: Beclomethasone 252 microg
Number of subjects: 10

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Antigen challenge
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Beclomethasone
Number of subjects: 10
Study: 12186344

Group type: EXPERIMENTAL
Intervention: Frialit-2 implants used in bone reconstruction
Number of subjects: 29
Study: 10687523

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Flurbiprofen (100 mg loading dose and then 50 mg every 6 h)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Tramadol (100 mg loading dose and then 100 mg every 6 h)
Number of subjects: 49

Group type: EXPERIMENTAL
Intervention: Combination of flurbiprofen and tramadol
Number of subjects: 49
Study: 8579082

Group type: EXPERIMENTAL
Intervention: Antibiotics plus rh‐GMCSF (3 micrograms/kg per day i.v.)
Number of subjects: 107

Group type: COMPARATOR
Intervention: Antibiotics alone (ticarcillin‐clavulanate + netilmicin)
Number of subjects: 107

Group type: EXPERIMENTAL
Intervention: Antibiotics plus rh‐GMCSF
Number of subjects: 107

Group type: COMPARATOR
Intervention: Antibiotics alone
Number of subjects: 107
Study: 1937326

Group type: EXPERIMENTAL
Intervention: cefuroxime axetil 2 x 500 mg/d
Number of subjects: 128

Group type: COMPARATOR
Intervention: ofloxacin 2 x 200 mg/d
Number of subjects: 128
Study: 7270864

Group type: EXPERIMENTAL
Intervention: Dantrolene (2 x 1 mg/kg)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Dantrolene
Number of subjects: 20
Study: 30442467

Group type: EXPERIMENTAL
Intervention: Piriformis-sparing minimally invasive approach
Number of subjects: 100

Group type: COMPARATOR
Intervention: Standard posterior approach
Number of subjects: 100
Study: 28797666

Group type: EXPERIMENTAL
Intervention: Pain Neurophysiology Education (PNE)
Number of subjects: 72
Study: 26537182

Group type: EXPERIMENTAL
Intervention: Metformin
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin (females)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Metformin (males)
Number of subjects: 0
Study: 24091128

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) plus Epirubicin (75 mg/m2) plus Bevacizumab (15 mg/kg) every 3 weeks for up to 9 cycles followed by Bevacizumab (15 mg/kg) until disease progression
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Docetaxel (75 mg/m2) plus Epirubicin (75 mg/m2) plus Bevacizumab (15 mg/kg)
Number of subjects: 83
Study: 21846852

Group type: EXPERIMENTAL
Intervention: Pegloticase 8 mg biweekly (every 2 weeks)
Number of subjects: 225

Group type: EXPERIMENTAL
Intervention: Pegloticase alternating with placebo (monthly treatment group)
Number of subjects: 225

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 225
Study: 19425900

Group type: EXPERIMENTAL
Intervention: Chewing gum
Number of subjects: 492

Group type: COMPARATOR
Intervention: Abstaining from chewing gum
Number of subjects: 492

Group type: COMPARATOR
Intervention: Chewing gum / Abstaining from chewing gum
Number of subjects: 492
Study: 17720071

Group type: EXPERIMENTAL
Intervention: Akreos Adapt Advanced Optics IOL
Number of subjects: 80

Group type: COMPARATOR
Intervention: Tecnis Z9000 IOL
Number of subjects: 80
Study: 15480643

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy at energy level E1=0.15 mJ/mm2
Number of subjects: 90

Group type: EXPERIMENTAL
Intervention: Extracorporeal shock wave therapy at energy level E2=0.44 mJ/mm2
Number of subjects: 90

Group type: COMPARATOR
Intervention: Sham treatment
Number of subjects: 90
Study: 11738123

Group type: EXPERIMENTAL
Intervention: Diuretic (chlorthalidone)
Number of subjects: 42419

Group type: EXPERIMENTAL
Intervention: 3-hydroxy-3-methyl-glutaryl coenzyme A reductase inhibitor (pravastatin)
Number of subjects: 42419
Study: 9740604

Group type: EXPERIMENTAL
Intervention: Nitrendipine monotherapy (average dose 23.4 mg/d)
Number of subjects: 2398

Group type: EXPERIMENTAL
Intervention: Nitrendipine with other treatments (average dose 35.7 mg/d)
Number of subjects: 2398

Group type: COMPARATOR
Intervention: Nitrendipine monotherapy
Number of subjects: 2398

Group type: EXPERIMENTAL
Intervention: Nitrendipine monotherapy (matched analysis)
Number of subjects: 2398
Study: 8147338

Group type: EXPERIMENTAL
Intervention: Ferrous sulphate (60 or 120 mg Fe/d)
Number of subjects: 80
Study: 3170119

Group type: EXPERIMENTAL
Intervention: 62.5 micrograms PGF2 alpha
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 125 micrograms PGF2 alpha
Number of subjects: 45

Group type: EXPERIMENTAL
Intervention: 250 micrograms PGF2 alpha
Number of subjects: 45

Group type: COMPARATOR
Intervention: Control (50 microliter of saline)
Number of subjects: 45
Study: 31542290

Group type: EXPERIMENTAL
Intervention: Coronary bioresorbable scaffolds
Number of subjects: 0
Study: 28402704

Group type: EXPERIMENTAL
Intervention: Endoscopic Papillary Large Balloon Dilation (EPLBD)
Number of subjects: 124

Group type: COMPARATOR
Intervention: Endoscopic Sphincterotomy (ES)
Number of subjects: 124
Study: 25159291

Group type: EXPERIMENTAL
Intervention: McKenzie therapy
Number of subjects: 271

Group type: COMPARATOR
Intervention: Electrophysical agents
Number of subjects: 271
Study: 23724572

Group type: EXPERIMENTAL
Intervention: Hypnosis plus placebo
Number of subjects: 94

Group type: COMPARATOR
Intervention: Diazepam plus muscle relaxation
Number of subjects: 94
Study: 21038024

Group type: EXPERIMENTAL
Intervention: Endoscopic sinus surgery (ESS)
Number of subjects: 68

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate nasal drops (FPND) 400 µg twice daily (b.i.d.)
Number of subjects: 68

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 68
Study: 18412295

Group type: EXPERIMENTAL
Intervention: Carotid endarterectomy in addition to best medical management
Number of subjects: 0

Group type: COMPARATOR
Intervention: Best medical management alone
Number of subjects: 0
Study: 16752139

Group type: EXPERIMENTAL
Intervention: Abstaining participants
Number of subjects: 50

Group type: COMPARATOR
Intervention: Smoking participants
Number of subjects: 50
Study: 12921396

Group type: EXPERIMENTAL
Intervention: Mixed-effects computation with random treatment-by-center interaction
Number of subjects: 0

Group type: COMPARATOR
Intervention: Fixed-effects, two-way analysis of variance
Number of subjects: 0
Study: 10919680

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate HFA 134a pMDIs (400, 1000, and 2000 microg doses)
Number of subjects: 23

Group type: COMPARATOR
Intervention: Fluticasone propionate HFA 134a pMDIs (125 and 250 microg strengths)
Number of subjects: 23

Group type: EXPERIMENTAL
Intervention: Fluticasone propionate HFA 134a pMDIs
Number of subjects: 23
Study: 8828766

Group type: EXPERIMENTAL
Intervention: Heparin-coated CPB system (HC group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Heparin-coated oxygenator and uncoated CPB circuit (HO group)
Number of subjects: 30

Group type: COMPARATOR
Intervention: Uncoated system (UC group)
Number of subjects: 30
Study: 1533728

Group type: EXPERIMENTAL
Intervention: Ipratropium bromide
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 3993041

Group type: EXPERIMENTAL
Intervention: therapeutic exercise alone
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: iodine therapy with iodine brine
Number of subjects: 123

Group type: EXPERIMENTAL
Intervention: remedial exercise plus iodine brine therapy
Number of subjects: 123

Group type: COMPARATOR
Intervention: rigidly controlled diabetic diet (common to all groups)
Number of subjects: 123
Study: 29338568

Group type: EXPERIMENTAL
Intervention: Pineapple flavored lactoferrin oral sachets 100 mg twice daily with health education (group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Total dose infusion (TDI) of low-molecular weight (LMW) iron dextran (group B)
Number of subjects: 120
Study: 30213214

Group type: EXPERIMENTAL
Intervention: Survey-only data collection
Number of subjects: 0

Group type: COMPARATOR
Intervention: Administrative-only data collection
Number of subjects: 0
Study: 27322478

Group type: EXPERIMENTAL
Intervention: AGTP (Adipose Graft Transposition Procedure)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: AGTP
Number of subjects: 10

Group type: COMPARATOR
Intervention: CABG (Control)
Number of subjects: 10
Study: 25424929

Group type: EXPERIMENTAL
Intervention: RV5 (live pentavalent rotavirus vaccine), 3 doses of 2 mL each, administered 28-42 days apart
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 300

Group type: EXPERIMENTAL
Intervention: RV5 (live pentavalent rotavirus vaccine)
Number of subjects: 300
Study: 22456294

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg administered 30 min before meals
Number of subjects: 12

Group type: COMPARATOR
Intervention: Vildagliptin 50 mg administered immediately before meals
Number of subjects: 12

Group type: EXPERIMENTAL
Intervention: Vildagliptin 50 mg (both regimens)
Number of subjects: 12
Study: 20626665

Group type: EXPERIMENTAL
Intervention: Metabolic syndrome (MetS) group
Number of subjects: 0

Group type: COMPARATOR
Intervention: No metabolic syndrome (non-MetS) group
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Participants with MetS compared to those without MetS
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Increasing number of components of MetS
Number of subjects: 0
Study: 17621619

Group type: EXPERIMENTAL
Intervention: Drug treatment for OAB
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Conservative management (lifestyle interventions, modification of fluid intake, physiotherapy including bladder retraining)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Surgery
Number of subjects: 0
Study: 15647406

Group type: EXPERIMENTAL
Intervention: Ciclesonide 800 microg
Number of subjects: 18

Group type: COMPARATOR
Intervention: Fluticasone propionate 1000 microg
Number of subjects: 18
Study: 12642201

Group type: EXPERIMENTAL
Intervention: Combined informative and physical rehabilitation program
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Informative groups (information and information+physical training)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: All programs (informative, physical, combined)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination program or information alone
Number of subjects: 0
Study: 10573067

Group type: EXPERIMENTAL
Intervention: 100 microg/day of G-CSF
Number of subjects: 172

Group type: EXPERIMENTAL
Intervention: 300 microg/day of G-CSF
Number of subjects: 172

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 172
Study: 8915746

Group type: COMPARATOR
Intervention: Bleomycin
Number of subjects: 24

Group type: EXPERIMENTAL
Intervention: ABV (doxorubicin, bleomycin, and vincristine)
Number of subjects: 24
Study: 1888645

Group type: EXPERIMENTAL
Intervention: Plain aspirin 300 mg daily
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Plain aspirin 600 mg four times daily
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 300 mg daily
Number of subjects: 5

Group type: EXPERIMENTAL
Intervention: Enteric-coated aspirin 600 mg four times daily
Number of subjects: 5

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 5
Study: 6139317

Group type: EXPERIMENTAL
Intervention: Timiperone
Number of subjects: 88

Group type: COMPARATOR
Intervention: Clocapramine
Number of subjects: 88
Study: 30783071

Group type: EXPERIMENTAL
Intervention: PEPS + TAU
Number of subjects: 80

Group type: COMPARATOR
Intervention: TAU
Number of subjects: 80
Study: 30306759

Group type: EXPERIMENTAL
Intervention: Influenza vaccination
Number of subjects: 100000

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 100000
Study: 27309266

Group type: EXPERIMENTAL
Intervention: Er:YAG laser for 10 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Er:YAG laser for 30 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Er, Cr:YSGG laser for 10 seconds
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Er, Cr:YSGG laser for 30 seconds
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group (unexposed)
Number of subjects: 0
Study: 24942954

Group type: EXPERIMENTAL
Intervention: Comprehensive dietary guidelines provided in an educational booklet for 4-6 weeks during disease flare.
Number of subjects: 112

Group type: COMPARATOR
Intervention: Control group (no dietary guidelines).
Number of subjects: 112
Study: 22471650

Group type: EXPERIMENTAL
Intervention: 4‐Health Educational Program
Number of subjects: 150

Group type: COMPARATOR
Intervention: Healthy Living Information
Number of subjects: 150
Study: 20217051

Group type: EXPERIMENTAL
Intervention: Nicotine cigarettes
Number of subjects: 71

Group type: COMPARATOR
Intervention: Denic cigarettes
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Nicotine cigarettes after overnight abstinence
Number of subjects: 71

Group type: EXPERIMENTAL
Intervention: Speech preparation session
Number of subjects: 71
Study: 17516056

Group type: EXPERIMENTAL
Intervention: Standard conditioning (painful electrical conditioning stimuli applied over the sural nerve 100 ms before test stimuli)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Random sequences (test‐only and conditioning‐test combinations in a double‐blind, random order)
Number of subjects: 10
Study: 15101858

Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB) with 10 ml of 1% lidocaine
Number of subjects: 20

Group type: COMPARATOR
Intervention: Intramuscular injection (IM)
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Stellate ganglion block (SGB)
Number of subjects: 20
Study: 11725478

Group type: EXPERIMENTAL
Intervention: Interim analysis methodology
Number of subjects: 13282

Group type: COMPARATOR
Intervention: Not applicable
Number of subjects: 13282
Study: 9829444

Group type: EXPERIMENTAL
Intervention: Ciprofloxacin (CIP) 500 mg b.i.d. for 10 days
Number of subjects: 1414

Group type: COMPARATOR
Intervention: Cefuroxime axetil (CA) 250 mg b.i.d. for 10 days
Number of subjects: 1414
Study: 7917535

Group type: EXPERIMENTAL
Intervention: Etretinate (50 mg/day for the first month, followed by 25 mg/day for the following months)
Number of subjects: 316

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 316

Group type: EXPERIMENTAL
Intervention: Etretinate
Number of subjects: 316
Study: 2744731

Group type: EXPERIMENTAL
Intervention: Recombinant human alpha-interferon (2.5, 5.0 or 10 X 10(6) per m2, intramuscularly, three times per week, for 24 weeks)
Number of subjects: 16

Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Reactivation of chronic hepatitis B
Number of subjects: 16

Group type: EXPERIMENTAL
Intervention: Fluctuations in serum ALT values
Number of subjects: 16

Group type: COMPARATOR
Intervention: Conventional indices (serum albumin, bilirubin concentrations, prothrombin time)
Number of subjects: 16
Study: 332345

Group type: EXPERIMENTAL
Intervention: BCOP (BCNU, cyclophosphamide, Oncovin (vincristine), and prednisone)
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: COP (cyclophosphamide, Oncovin (vincristine), and prednisone)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Cycle-active therapy (methotrexate, cytosine arabinoside, and 6‐thioguanine)
Number of subjects: 298

Group type: COMPARATOR
Intervention: Good histologies
Number of subjects: 298
Study: 31752543

Group type: EXPERIMENTAL
Intervention: Immunoelectron microscopy (IEM) with gold‐labelled antibodies against kappa light chains, lambda light chains, transthyretin and amyloid A
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Laser microdissection followed by tandem mass spectrometry (LMD‐MS)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Mass spectrometry (MS)
Number of subjects: 106

Group type: EXPERIMENTAL
Intervention: Combined use of IEM and LMD‐MS
Number of subjects: 106
Study: 31084337

Group type: EXPERIMENTAL
Intervention: Financial incentives (21 months)
Number of subjects: 17502

Group type: EXPERIMENTAL
Intervention: Action plans (9 months)
Number of subjects: 17502

Group type: EXPERIMENTAL
Intervention: National score (4 indicators)
Number of subjects: 17502

Group type: EXPERIMENTAL
Intervention: Access to stroke units
Number of subjects: 17502
Study: 28502545

Group type: EXPERIMENTAL
Intervention: EVAR with preservation of antegrade internal iliac artery perfusion using iliac branched devices (EVAR-IBD)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Standard EVAR
Number of subjects: 330
Study: 25409112

Group type: EXPERIMENTAL
Intervention: Patient-Centered Outcomes and Coordinated-Care Management (PCCM) approach
Number of subjects: 1506

Group type: COMPARATOR
Intervention: Conventional Diagnostic and Treatment Outpatient Medical Care (CONV) approach
Number of subjects: 1506
Study: 23341418

Group type: EXPERIMENTAL
Intervention: Massage therapy (20-minute interventions pre- and post-surgery)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Structured attention (20-minute interventions pre- and post-surgery)
Number of subjects: 60
Study: 21447470

Group type: EXPERIMENTAL
Intervention: WB-GTH intervention
Number of subjects: 272
Study: 19375959

Group type: EXPERIMENTAL
Intervention: Adjustable training martingales (TM)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Elasticised rein inserts (RI)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Plain reins (Control)
Number of subjects: 13
Study: 16971801

Group type: EXPERIMENTAL
Intervention: Multishot DW‐PROPELLER
Number of subjects: 12

Group type: COMPARATOR
Intervention: Single‐shot DW‐SE‐EPI
Number of subjects: 12
Study: 15274665

Group type: EXPERIMENTAL
Intervention: H. pylori eradication treatment
Number of subjects: 96

Group type: COMPARATOR
Intervention: H. pylori-positive gastritis
Number of subjects: 96
Study: 11308438

Group type: EXPERIMENTAL
Intervention: Single blinding
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Double blinding
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Triple blinding
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Single blinding (textbook definition)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Double blinding (textbook definition)
Number of subjects: 91

Group type: EXPERIMENTAL
Intervention: Triple blinding (textbook definition)
Number of subjects: 91
Study: 9428580

Group type: EXPERIMENTAL
Intervention: Avocado-enriched vegetarian diet (AVD)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Standard vegetarian diet (ALVD)
Number of subjects: 13

Group type: COMPARATOR
Intervention: Avocado-added free diet (FDWA)
Number of subjects: 13
Study: 8214744

Group type: EXPERIMENTAL
Intervention: Mechanical ventilation
Number of subjects: 6

Group type: COMPARATOR
Intervention: Spontaneous ventilation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia (30 min after application) during spontaneous ventilation
Number of subjects: 6

Group type: EXPERIMENTAL
Intervention: Thoracic epidural anesthesia
Number of subjects: 6
Study: 3441105

Group type: EXPERIMENTAL
Intervention: Combination of timolol 0.5% and pilocarpine 2%
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Combination of timolol 0.5% and pilocarpine 4%
Number of subjects: 0
Study: 31084617

Group type: EXPERIMENTAL
Intervention: ICD-11 guidelines
Number of subjects: 2288

Group type: COMPARATOR
Intervention: ICD-10 guidelines
Number of subjects: 2288
Study: 29378981

Group type: EXPERIMENTAL
Intervention: Diode laser at 1.2 W
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diode laser at 2 W
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Diode laser at 3 W
Number of subjects: 36

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 36
Study: 26516311

Group type: EXPERIMENTAL
Intervention: Furocyst (Trigonella foenum-graecum seed extract, 2 capsules of 500 mg each/day)
Number of subjects: 50
Study: 23213055

Group type: EXPERIMENTAL
Intervention: Tamoxifen for 5 years (arm A)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Tamoxifen for 2 years followed by anastrozole for 3 years (arm B)
Number of subjects: 0
Study: 21982456

Group type: EXPERIMENTAL
Intervention: Real-time automated electronic medical record alerts for patients with estimated glomerular filtration rates <45 mL/min/1.73 m(2) recommending renal referral and urine albumin quantification if not done within the prior year.
Number of subjects: 248

Group type: COMPARATOR
Intervention: Control group (no automated alerts).
Number of subjects: 248
Study: 18300666

Group type: EXPERIMENTAL
Intervention: Continuous temperature-controlled cryotherapy
Number of subjects: 53

Group type: COMPARATOR
Intervention: Ice therapy
Number of subjects: 53

Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 53
Study: 16525857

Group type: EXPERIMENTAL
Intervention: 0.5 mg lorazepam
Number of subjects: 64

Group type: EXPERIMENTAL
Intervention: 1 mg lorazepam
Number of subjects: 64

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 64
Study: 14756914

Group type: EXPERIMENTAL
Intervention: 4800 microg retinol (vitamin A) + 120 mg Fe + 500 microg folic acid
Number of subjects: 276

Group type: COMPARATOR
Intervention: 120 mg Fe + 500 microg folic acid (without vitamin A)
Number of subjects: 276

Group type: COMPARATOR
Intervention: Governmental Fe supplementation programme (control group)
Number of subjects: 276
Study: 11359657

Group type: EXPERIMENTAL
Intervention: rHuIL-12 administered by subcutaneous injection at a maintenance dose of 1.25 microg/kg on days 1, 8, and 15 of each 28-day cycle.
Number of subjects: 46

Group type: COMPARATOR
Intervention: IFN-alpha 2a administered at 9 million units by subcutaneous injection three times per week.
Number of subjects: 46
Study: 9408720

Group type: EXPERIMENTAL
Intervention: Cumulative meta-analysis with classical monitoring boundaries
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Randomized controlled trial
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Optimal information size for a meta-analysis
Number of subjects: 0